The Drug Controller General of India (DCGI) has released draft guidelines that make it mandatory for clinical research organisations to conduct an audiovisual recording of the trial patients inform

Initiates petition in change.org asking SC to allow review and approval process to resume

People for the Advancement of Clinical Research, (PACR) India, a group that claims to comprise ordinary healthy citizens, patients, government officials, health enterprise professionals, educators and patient advocacy groups have initiated a petition in the popular advocacy site change-.org asking the Supreme Court to allow the review and approval process for clinical trial applications to resume.

Each of the 3 drugs— Dasatinib Trastuzumab & Ixabepilone—costs 1L for a month’s dose

The government has appointed a panel to look into issues related to compulsory licensing of drugs and whether cheaper versions of cancer medicines Trastuzumab, Ixabepilone and Dasatinib can be launched under the provision, a person with knowledge of the development said. According to the person, the health ministry has sent its proposal regarding compulsory licensing for the three drugs to the Department of Industrial Policy and Promotion (DIPP), which in turn has sought the opinion of the department of pharmaceuticals. Srikant Jena, Minister of State for Chemicals and Fertilisers, however, denied having received any note.